top of page

Insmed's CEO on the success of brensocatib in bronchiectasis and what it means for the company

Will Lewis describes last week's data and what means not just for bronchiectasis but also as a broader proof of concept for DPP1 inhibition, and he also highlights Insmed's other programs.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

bp-logo.png

Breakthrough Properties is a life science real estate company that is exclusively focused on delivering cutting-edge environments for the life science industry. With a portfolio of roughly 5 million square feet across the US, UK and continental Europe, Breakthrough has emerged as a leading partner for high-growth biotechs and pharmas around the world. 

bottom of page